Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Squamous Cell 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Squamous Cell 1Melanoma 1Lymphoma 1Liver Neoplasms 1Hodgkin Disease 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

Sorafenib 9Radiofrequency Ablation 7Oxaliplatin 7Fluorouracil 6Doxorubicin 6Neoadjuvant Therapy 5toripalimab 4lenvatinib 4Injections 4Chemotherapy, Adjuvant 4Bevacizumab 4sintilimab 3pembrolizumab 3Ultrasonography 3Thalidomide 3Leucovorin 3Irinotecan 3Cisplatin 3tislelizumab 2durvalumab 2camrelizumab 2anlotinib 2Walking Speed 2Standard of Care 2Radiosurgery 2Oncolytic Virotherapy 2Metformin 2Liver Transplantation 2Laparoscopy 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Liver Neoplasms × advexin × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡